New PET tracer aims to spot Parkinson's in the brain
NCT ID NCT07640542
First seen Jun 18, 2026 · Last updated Jun 19, 2026 · Updated 1 time
Summary
This early-phase trial tests a new radioactive tracer called [11C]MODAG-005 that binds to abnormal protein clumps in the brain linked to Parkinson's disease and multiple system atrophy. Nine participants (patients with Parkinson's, MSA, and healthy volunteers) will receive the tracer and undergo PET scans to see if it safely highlights these protein deposits. The goal is to improve diagnosis and distinguish between these similar conditions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE (PD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
[11C]MODAG-005 (a radioactive tracer for PET scans)
What this could lead to
If successful, this could lead to a new way to diagnose Parkinson's disease and multiple system atrophy more accurately using brain scans.
What could go wrong
This is a very early, small pilot study with only 9 participants. The tracer may not reliably distinguish between diseases or may have safety issues.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.